The hospitalist at Memorial Sloan Kettering Cancer Center highlighted important takeaways from a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.
Study results presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium revealed that investigators observed a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera).
In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, explained what she believes is the greatest takeaway from the study findings.
Transcription:
The biggest takeaway point that I emphasized in my presentation at [the meeting] and I’ll emphasize now is that this treatment looks to have a meaningful benefit in these higher-grade, more advanced [NETs]. We observed about a 69% disease control rate in this population, which I think is very encouraging.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Trastuzumab Deruxtecan Showcases Clinical Efficacy in HER2+ Gynecological Cancers
November 20th 2023Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.
Mirvetuximab Soravtansine Yields Meaningful OS in Platinum-Resistant Ovarian Cancer
November 17th 2023Data from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a new standard of care for patients with folate receptor α–positive, platinum-resistant ovarian cancer, says Kathleen N. Moore, MD, MS.
Induction Chemotherapy/CRT Improves Efficacy in Advanced Cervical Cancer
November 17th 2023Results from the phase 3 GCIG INTERLACE trial highlight progression-free survival and overall survival improvements with induction chemotherapy plus chemoradiotherapy for patients with locally advanced cervical cancer.